Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

News You Need to Know Today
News Alert: FDA approves first anti-inflammatory drug for treating cardiovascular disease
Tuesday, June 20, 2023
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

News Alert

FDA approves colchicine, the first anti-inflammatory drug for treating cardiovascular disease

The FDA's approval of colchicine, which is marketed and sold under the name Lodoco, is expected to have a big impact on cardiac care and outcomes.

READ MORE >
The U.S. Food and Drug Administration (FDA) priority review, the FDA has cleared the Agepha Pharma USA LLC's drug Lodoco (colchicine) as the first anti-inflammatory atheroprotective cardiovascular treatment. Colchicine prevents coronary artery plaque inflammation, heart inflammation. Colchicine for coronary artery disease. Colchicine for coronary inflammation FDA Approves Colchicine for Decreasing CV Events FDA Approves Colchicine for decreasing inflammation caused by coronary atherosclerosis.
Share on Twitter Share on Facebook Share on Linkedin

FDA approves colchicine, the first anti-inflammatory drug for treating cardiovascular disease

Share on Twitter Share on Facebook Share on Linkedin
The U.S. Food and Drug Administration (FDA) priority review, the FDA has cleared the Agepha Pharma USA LLC's drug Lodoco (colchicine) as the first anti-inflammatory atheroprotective cardiovascular treatment. Colchicine prevents coronary artery plaque inflammation, heart inflammation. Colchicine for coronary artery disease. Colchicine for coronary inflammation FDA Approves Colchicine for Decreasing CV Events FDA Approves Colchicine for decreasing inflammation caused by coronary atherosclerosis.
The FDA's approval of colchicine, which is marketed and sold under the name Lodoco, is expected to have a big impact on cardiac care and outcomes.
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

TAVR for moderate aortic stenosis | BP drug recalled | Stroke prevention device fails | New Medicare cuts | CCTA-guided PCI
A new way to think about the heart health of women | GLP-1 drugs vs. metformin | Cannabis use may increase risk of CVD, stroke
New Medicare payment cuts | Telemedicine vs. in-person cardiology visits | FDA confirms Class I recall | Startup raises $160M
FDA approves transcatheter treatment for PVL | CCTA-guided PCI | Real-world RDN outcomes | J&J launches new IVL catheter
CCTA vs. IVUS for PCI guidance: Carlos Collet reviews the data | The real-world benefits of RDN | New TAVR tech falls short
TAVR Highlights: New data on treating moderate AS | CMS may expand coverage again | Is surgical backup still necessary?
GLP-1 drugs vs. metformin | BP drug recalled | The health risks of cannabis use | Energy drinks linked to heart issues
Newsletter archive
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
  • Press Releases
  • Submit Press Release
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
Design by Adaptive Theme
Trimed Popup